Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus.

@article{Hoeben2016PopulationPM,
  title={Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus.},
  author={Eef Hoeben and Willem de Winter and Martine Neyens and Damayanthi Devineni and An M. Vermeulen and A. Michael Dunne},
  journal={Clinical pharmacokinetics},
  year={2016},
  volume={55 2},
  pages={
          209-23
        }
}
BACKGROUND AND OBJECTIVES Canagliflozin is an orally active, reversible, selective sodium-glucose co-transporter-2 inhibitor. A population pharmacokinetic (popPK) model of canagliflozin, including relevant covariates as sources of inter-individual variability, was developed to describe phase I, II, and III data in healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). METHODS The final analysis included 9061 pharmacokinetic (PK) samples from 1616 volunteers enrolled in nine… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

Similar Papers

Loading similar papers…